

STATEMENT
To pass the audited financial statements of 2020

To: The General Meeting of Shareholders

In pursuant to the Law on Enterprises;

In pursuant to the Charter of Imexpharm Corporation;

The Board of Directors (BOD) respectfully submits to the General Meeting of Shareholders for approval the 2020 financial statements of Imexpharm Corporation, audited by PwC (Vietnam) Company Limited.

The audited financial statements of 2020 have been disclosed in accordance with the regulations and also posted on the website of the Company (<http://www.imexpharm.com/doi-tac-nha-dau-tu/>), including:

1. Corporate information;
2. Statement of the Board of Management;
3. Independent auditor's report;
4. Balance sheet (Form B01-DN);
5. Income Statement (Form B02-DN);
6. Cash flow Statement (Form B03-DN);
7. Notes to the financial statements (Form B09-DN).

In which

There are some typical indicators in the financial statements 2020

No	Typical indicators	Unit	Year 2020	Year 2019
1	Total assets	dong	2,096,455,266,870	1,847,174,315,262
2	Total net revenue and income	dong	1,382,337,463,462	1,420,711,494,579
3	Net revenue	dong	1,369,421,714,781	1,402,454,493,864
4	Profit before tax	dong	255,441,337,429	202,429,110,631
5	Profit after tax	dong	209,696,878,289	162,386,686,793

Respectfully submit to the General Meeting of Shareholders to review and approve.

**ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRMAN**

Mr. Nguyen Quoc Dinh